Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (NCT07855692) titled 'The Clinical Trial of Tamibarotene for Patients With HFpEF (RELIEF Trial)' on Sept. 28.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: Nagoya University
Condition:
HFpEF - Heart Failure With Preserved Ejection Fraction
Intervention:
Drug: Tamibarotene
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: October 1, 2026
Target Sample Size: 90
Countries of Recruitment:
Japan
To know more, visit http...